Read in and find out
View publications of the SATURN3 consortium or individual members. Once new publications are available, we list them here. Open access listings are linked directly to the full text version. All others lead to the respective journal repository or publisher. For SATURN3 press releases, please go to News.
List of SATURN3 Publications (selected):
2026
-
Hlevnjak M, Heublein S, Thewes V. et al. Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience. Int J Cancer. 2026 (PMID: 41170836)
-
Peng J, Yang J, Antonopoulou G. et al. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Nat Commun. 2026 (PMID: 41651844)
-
Vaquero-Siguero N., Georgakopoulos N., Puschhof. MC., Jackstadt R. et al. TROP2 targeting reveals therapy-driven cell state dynamics and vulnerabilities in colorectal cancer. Nature 2026 (in press)
2025
-
Cheytan T, Schneider M, Wurth R, et al. Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism (PMID: 40057730). Mol Cancer. 2025.
-
Denk D, Ramakrishnan M, Conche C, et al. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis (PMID: 40023157). Immunity. 2025.
-
Denk D, Singh A, Kasler HG, Greten FR et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nat Aging. 2025 Nov;5(11):2309-2322. doi: 10.1038/s43587-025-00996-x. Epub 2025 (PMID: 41174221).
-
Denkert C, Rachakonda S, Karn T, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB) (PMID: 39933898). Cancer Cell. 2025.
-
Dietz-Fricke C, Greten FR et al. Large vesicles from ageing neutrophils: novel safeguards for the resolution of inflammation. Signal Transduct Target Ther. 2025 (PMID: 40383810)
-
Ganesan K., Billard E., Schwarz RF. PhytClust: efficient and optimal node clustering in phylogenetic trees (under review). bioRxiv 2025. https://doi.org/10.64898/2025.12.11.693738
-
Ghadimi M, Pelzer U, Besselink MG, et al. Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial (PMID: 39915735). BMC Cancer. 2025.
-
Heyl F., Gassenschmidt J, Heine L, Voigt F., Kleesiek J., Stegle O., Siveke JT., Boerries M., Schwarz RF., Godfrey L. LiMeTrack: A lightweight biosample management platform for the multicenter SATURN3 consortium (under review). bioRxiv 2025. https://doi.org/10.1101/2025.09.01.25334868
-
Hofer S, Frasch L, Brajkovic S, et al. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response (PMID: 39838187). Mol Syst Biol. 2025.
-
Kennel KB, Greten FR. The immune microenvironment of colorectal cancer. Nat Rev Cancer. 2025 (PMID: 40983666).
-
Keyl J, Keyl P, Montavon G, et al. Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence (PMID: 39885364). Nat Cancer. 2025.
-
Körber V, Jakobsen NA, Ansari-Pour N. et al. Detecting and quantifying clonal selection in somatic stem cells. Nat Genet. 2025 (PMID: 40610627)
-
Lahusen A, Lutz MP, Siveke JT, et al. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Mol Cancer. 2025 (PMID: 40696453)
-
Metzenmacher M, Zaun G, Trajkovic-Arsic M, et al. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA (PMID: 39478658). Mol Oncol. 2025.
-
Pixberg C, Maurer C, Zapatka M, Erben V, Schumacher-Wulf E, Thewes V, Lichter P, Schneeweiss A. COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study. Geburtshilfe Frauenheilkd. 2025 (PMID: 40510401)
-
Rademacher A, Huseynov A, Bortolomeazzi M, et al. Comparison of spatial transcriptomics technologies using tumor cryosections. Genome Biol. 2025 (PMID: 40542418)
-
Rödel F, Fleischmann M, Diefenhardt M, Dapper H, Hoffmann A, Rödel C, Martin D, Fokas E. Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer. Nat Rev Clin Oncol 2025 (PMID: 40360682).
-
Schwerd-Kleine P, Wurth R, Cheytan T, et al. Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility (PMID: 40022208). Int J Cancer. 2025.
-
Starostecka M, Jeong H, Hasenfeld P, et al. Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model (PMID: 39993200). Proc Natl Acad Sci U S A. 2025.
-
Steup C, Kennel KB, Neurath MF, Fichtner-Feigl S, Greten FR. Current and emerging concepts for systemic treatment of metastatic colorectal cancer. Gut. 2025 (PMID: 41047178)
-
Tapia Contreras C, Falke JD, Seifert DM, et al. KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening (PMID: 39253995). Mol Oncol. 2025.
-
Thiel V, Renders S, Panten J, et al. Characterization of single neurons reprogrammed by pancreatic cancer (PMID: 39961335). Nature. 2025.
-
Wittenzellner K, Lengl M, Reichert M. et al. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. JCI Insight. 2025 (PMID: 40424076).
-
Wurth R, Donato E, Michel LL, et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling (PMID: 39753722). Nat Cancer. 2025.
-
Zhao B, Fang R, Schurmann H, et al. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma (PMID: 40188436). Cell Rep. 2025.
2024
-
An J, Kurilov R, Peccerella T, et al. Metavert synergises with standard cytotoxics in human PDAC organoids and is associated with transcriptomic signatures of therapeutic response (PMID: 39217851). Transl Oncol. Epub 2024.
-
Denkert C, Schneeweiss A, Rey J, et al. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer (GeparNuevo) (PMID: 39566464). Cell Rep Med. 2024.
-
Fan S, Fleischer JR, Dokshokova L, et al. High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern (PMID: 39072289). Mol Ther Oncol. 2024.
-
Foersch S, Schmitt M, Litmeyer AS, et al. TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis (PMID: 39177576). J Pathol Clin Res. 2024.
-
Godfrey LK, Forster J, Liffers ST, et al. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation (PMID: 38229153). Clin Epigenetics. 2024.
-
Hasselluhn MC, Schlosser D, Versemann L, et al. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies (PMID: 37913894). Gastroenterology. 2024.
-
Jank P, Karn T, van Mackelenbergh M, et al. An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials (PMID: 38837894). Clin Cancer Res. 2024.
-
Papargyriou A, Najajreh M, Cook DP, et al. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma (PMID: 39658630). Nat Biomed Eng. 2024.
-
Sanna FC, Benesova I, Pervan P, et al. IL-2 and TCR stimulation induce expression and secretion of IL-32beta by human T cells (PMID: 39211051). Front Immunol. 2024.
-
Schneider C, Hilbert J, Genevaux F, et al. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction (PMID: 38885414). Adv Sci (Weinh). 2024.
-
Siveke J.T., Dorman K., Siegler G.M., Seufferlein T., Trojan J., Waldschmidt D.T., Koenig A.O., Schipp D., Liffers S.T., Kunzmann V. 1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study. Conference contribution (ESMO 2024).
-
Veghini L, Pasini D, Fang R, et al. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer (PMID: 39627211). Nat Commun. 2024.
2023
-
Farin HF, Mosa MH, Ndreshkjana B, et al. Colorectal Cancer Organoid-Stroma Biobank Allows Subtype-Specific Assessment of Individualized Therapy Responses (PMID: 37489084). Cancer Discov. 2023.
-
Fleischer JR, Schmitt AM, Haas G, et al. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution (PMID: 36691028). Mol Cancer. 2023.
-
Heine L, Hörst F, Nasca E, et al. Conference contribution: Lean Study Host: Towards an Automated Pipeline for Multi-Center Study Hosting. 57th Hawaii International Conference on System Sciences HICSS 2023.
-
Kessler L, Hirmas N, Pabst KM, et al. (68)Ga-Labeled Fibroblast Activation Protein Inhibitor ((68)Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the (68)Ga-FAPI PET Observational Trial (PMID: 37973185). J Nucl Med. 2023.
-
Knoblauch M, Ma T, Beirith I, et al. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture (PMID: 37470855). J Cancer Res Clin Oncol. Epub 2023.
-
Liffers ST, Godfrey L, Frohn L, et al. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype (PMID: 35944927). Gut. 2023.
-
Reissig TM, Tzianopoulos I, Liffers ST, et al. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer (PMID: 37148593). ESMO Open. Epub 2023.
-
Saini M, Schmidleitner L, Moreno HD, et al. Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer (PMID: 37257449). Cell Rep. Epub 2023.
-
Sant P, Rippe K and Mallm JP. Approaches for single-cell RNA sequencing across tissues and cell types (PMID: 37062951). Transcription. 2023.
-
Seufert I, Sant P, Bauer K, Syed AP, Rippe K and Mallm J-P. Enhancing sensitivity and versatility of Tn5-based single cell omics. Front. Epigenet. Epigenom. 2023 (doi: 10.3389/freae.2023.1245879)
-
Wiedmann L, De Angelis Rigotti F, Vaquero-Siguero N, et al. HAPLN1 potentiates peritoneal metastasis in pancreatic cancer (PMID: 37095087). Nat Commun. 2023.
2022
-
Heid I, Münch C, Karakaya S, et al. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma (PMID: 36494842). Cancer Metab. 2022.
-
Keyl J, Kasper S, Wiesweg M, et al. Multimodal survival prediction in advanced pancreatic cancer using machine learning (PMID: 35988455). ESMO Open. Epub 2022.
